HENDERSON, Nev., June 27,
2024 /PRNewswire/ -- VolitionRx Limited (NYSE
AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company,
has issued a mid-year review to stockholders, ahead of its Annual
Meeting of Stockholders to be held on July 2, 2024.
Volition's mid-year review encompasses key highlights
including:
- Expanding access to the Nu.Q® Vet Cancer Test – now
available for purchase in 15 countries
worldwide.
- Engaging in active commercial discussions with significant
players in the liquid biopsy, IVD, sepsis and oncology
space.
- Preparing Data Rooms for potential near-term licensing
opportunities.
To find out more about Volition's achievements, please read the
company's mid-year review here.
Cameron Reynolds, President and
Group Chief Executive Officer, said:
"So far this year we have successfully supported our veterinary
licensing and distribution partners to launch our Nu.Q® Vet
Cancer test and progressed our Nu.Q® NETs product for sepsis,
Nu.Q® Lung Cancer and Capture-PCR™ technologies to be
ready for licensing.
"We have a large amount of study data that we expect is close to
being ready for inclusion in the data rooms and we have interest
from key industry players. Our focus in the second half of 2024
will include negotiating our first licensing deal in the human
space.
"We believe we have made great progress in our mission
throughout the first half of 2024; some fantastic achievements by
our whole team across the different pillars, further broadening and
strengthening our Intellectual Property portfolio and representing,
in our opinion, several significant commercial opportunities that
are ready for commercialization through licensing. We have plans in
place for the remainder of this year and beyond. Exciting times
ahead!"
Volition is developing simple, easy-to-use, cost-effective blood
tests to help diagnose and monitor a range of life-altering
diseases in both humans and animals. For more information about
Volition's technology go to: www.volition.com
About Volition
Volition is a multi-national company focused on advancing the
science of epigenetics. Volition is dedicated to saving lives and
improving outcomes for people and animals with life-altering
diseases through earlier detection, as well as disease and
treatment monitoring.
Through its subsidiaries, Volition is developing and
commercializing simple, easy to use, cost-effective blood tests to
help diagnose and monitor a range of diseases, including some
cancers and diseases associated with NETosis, such as sepsis. Early
diagnosis and monitoring have the potential not only to prolong the
life of patients, but also improve their quality of life.
Volition's research and development activities are centered in
Belgium, with an innovation
laboratory and office in the U.S. and additional offices in
London and Singapore.
The contents found at Volition's website address are not
incorporated by reference into this document and should not be
considered part of this document. Such website address is
included in this document as an inactive textual reference
only.
Media Enquiries:
Louise Batchelor/Debra Daglish, Volition,
mediarelations@volition.com +44 (0)7557 774620
Safe Harbor Statement
Statements in this press release may be "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, that concern matters that involve risks and
uncertainties that could cause actual results to differ materially
from those anticipated or projected in the forward-looking
statements. Words such as "expects," "anticipates," "intends,"
"plans," "aims," "targets," "believes," "seeks," "estimates,"
"optimizing," "potential," "goal," "suggests," "could," "would,"
"should," "may," "will" and similar expressions identify
forward-looking statements. These forward-looking statements relate
to, among other topics, Volition's expectations related to revenue
opportunities and growth, the timing, completion, success and
delivery of data from clinical studies, the timing of publications,
, the effectiveness and availability of Volition's blood-based
diagnostic, prognostic and disease monitoring tests, Volition's
ability to develop and successfully commercialize such test
platforms for early detection of cancer and other diseases as well
as serving as a diagnostic, prognostic or disease monitoring tools
for such diseases, and Volition's success in securing licensing
and/or distribution agreements with third parties for its products.
Volition's actual results may differ materially from those
indicated in these forward-looking statements due to numerous risks
and uncertainties, including, without limitation, results of
studies testing the efficacy of its tests. For instance, if
Volition fails to develop and commercialize diagnostic, prognostic
or disease monitoring products, it may be unable to execute its
plan of operations. Other risks and uncertainties include
Volition's failure to obtain necessary regulatory clearances or
approvals to distribute and market future products; a failure by
the marketplace to accept the products in Volition's development
pipeline or any other diagnostic, prognostic or disease monitoring
products Volition might develop; Volition's failure to secure
adequate intellectual property protection; Volition will face
fierce competition and Volition's intended products may become
obsolete due to the highly competitive nature of the diagnostics
and disease monitoring market and its rapid technological change;
downturns in domestic and foreign economies; and other risks,
including those identified in Volition's most recent Annual Report
on Form 10-K and Quarterly Reports on Form 10-Q, as well as other
documents that Volition files with the Securities and Exchange
Commission. These statements are based on current expectations,
estimates and projections about Volition's business based, in part,
on assumptions made by management. These statements are not
guarantees of future performance and involve risks, uncertainties
and assumptions that are difficult to predict. Forward-looking
statements are made as of the date of this press release, and,
except as required by law, Volition does not undertake an
obligation to update its forward-looking statements to reflect
future events or circumstances.
Nucleosomics™, Capture-PCR™ and Nu.Q® and their
respective logos are trademarks and/or service marks of VolitionRx
Limited and its subsidiaries. All other trademarks, service marks
and trade names referred to in this press release are the property
of their respective owners.
View original
content:https://www.prnewswire.com/news-releases/volitionrx-limited-issues-mid-year-review-ahead-of-2024-annual-meeting-302184456.html
SOURCE VolitionRx Limited